Skip to main content

Sophiris Bio Inc. (SPHS)

OTCMKTS: SPHS · IEX Real-Time Price · USD
0.0010 0.0000 (0.00%)
Oct 21, 2021 9:30 AM EDT - Market closed
Market Cap34,472
Revenue (ttm)n/a
Net Income (ttm)37,000
Shares Out32.07M
EPS (ttm)0.00
PE Ratio1.00
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume0
Open0.0010
Previous Close0.0010
Day's Range0.0010 - 0.0010
52-Week Range0.0010 - 0.0700
Beta1.80
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About SPHS

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatm...

IndustryBiotechnology
Founded2002
Employees6
Stock ExchangeOTCMKTS
Ticker SymbolSPHS
Full Company Profile

Financial Performance

Financial Statements

News

Sophiris Bio Announces Nasdaq Delisting

SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), ...

1 year ago - GlobeNewsWire